Fastox has presented its groundbreaking LAST technology during the Innovation Tank among 14 other start-up companies and was elected winner by a high-profile jury of medical experts and aesthetic industry leaders.
Fastox also participated to the “Present and future of toxins: what’s new?” session where it presented how its lead candidate, FTP-501, boosts the performance of botulinum toxin type A, leading to a faster onset and longer duration.
Replays of both presentations will be available on the IMCAS Academy website (IMCAS Academy - Aesthetic Surgery & Cosmetic Dermatology).
Fastox has discovered that combining botulinum toxin type A with fast-acting myorelaxant drugs could accelerate its onset of action, and, most importantly and surprisingly, could also significantly increase its duration of action.
Natalene Hoepffner, VP Marketing & Business Development at Fastox, comments: “Increasing BoNT/A duration of action, and boosting its performance, is a long-awaited innovation in the $6.5bn BoNT/A aesthetic and therapeutic markets. Our LAST technology opens new possibilities for both injectors and patients to get the optimal treatment they need”.
Fastox FTP-501 lead candidate should enter in clinical trials later this year.
About Fastox Pharma SA
For more information, please visit Home | Fastox Pharma
Fastox proprietary LAST® (Long-Acting Strengthened Toxin) technology allows to boost the performance of botulinum toxins A by combining them with safe myorelaxant drugs. The LAST™ technology has been validated in pre-clinical models and has shown to significantly increase the BoNT duration of action. Fastox will initiate its first-in-human clinical trial later year with its lead candidate FTP-501.
Contact:
Natalene Hoepffner, VP Marketing and Business Development
Fastox Pharma
+33 7 66 89 03 73